A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Sirolimus (Primary)
- Indications Giant lymph node hyperplasia
- Focus Therapeutic Use
Most Recent Events
- 11 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 10 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
- 10 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.